Clinical stage biotechnology company within the therapeutic field of life-threatening fungal diseases Biosergen AB (STO:BIOSGN) announced on Friday that it has successfully completed the treatment of the first patient with BSG005, a promising candidate for addressing invasive fungal infections, which claim 2.5 million lives annually.
The first patient, a 47-year-old male with uncontrolled diabetes and Mucormycosis, showed significant improvement, avoiding the need for lung removal surgery and experiencing no major safety issues. BSG005, designed to be safe, effective, and broad-spectrum, is a critical development amid rising resistance to current therapies.
Five trial sites in India are now fully operational, with recruitment efforts ongoing despite challenges posed by stringent eligibility criteria. Alkem Laboratories Ltd, a top Indian pharmaceutical company, actively supports the trial and will finance future phases in India. The trial is expected to complete by January 2025, with the goal of improving survival rates in patients with resistant fungal infections. Biosergen plans to provide ongoing updates on patient outcomes.
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
EydisBio receives USD2.6m SBIR grant from NIH's National Heart, Lung, and Blood Institute
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults